Please provide your email address to receive an email when new articles are posted on . The closer diabetic macular edema is to the center of the macula, the more likely it is to eventually involve ...
4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...
Amy Nguyen Howell, MD, MBA, highlights the importance of data collection, analysis, and the new ICD-10-CMZ codes in understanding and resolving health disparities in diabetic macular edema patient ...
17d
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Eylea just lost its data edge on archrival Lucentis in a key patient group. Two-year data from a head to head trial found that the two drugs were equally effective in patients with diabetic ...
Please provide your email address to receive an email when new articles are posted on . EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating ...
BOWIE, Md., Oct. 4, 2012 /PRNewswire/ -- Inovalon, Inc., a leading provider of data-driven healthcare solutions, today announced it has received the Encounter Data Processing System (EDPS) ...
Earlier this year, Regeneron ($REGN) scored a win when its eye drug Eylea outperformed a pair of Roche ($RHHBY) meds in a head-to-head study. And now, that win is ...
The Centers for Medicare & Medicaid Services has responded to a challenge to provide savings information on a competitive bidding process it's implementing for durable medical equipment. On Friday, ...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results